China Money Network
Login
Join

Akeso Develops Groundbreaking Antibody for Alzheimer’s Disease Trials

  • November 17, 2025 — 11:25 CST

This Data Is Locked!

This area is available only to Subscribers.

Akeso, Inc. has received approval to initiate clinical trials for Alzheimer's Disease in China with its novel bispecific antibody AK152.

The AK152 antibody targets both... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: